Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis

AUTOR(ES)

Delmas, G.

FONTE

American Society for Microbiology

RESUMO

Cochleates containing amphotericin B (CAMB) were administered orally at doses ranging from 0 to 40 mg/kg of body weight/day for 14 days in a murine model of systemic aspergillosis. The administration of oral doses of CAMB (20 and 40 mg/kg/day) resulted in a survival rate of 70% and a reduction in colony counts of more than 2 logs in lungs, livers, and kidneys. Orally administered CAMB shows promise for the treatment of aspergillosis.

Documentos Relacionados

• Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis.
• Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary Aspergillosis
• Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis
• Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.
• Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model